LFMD241220C7000
- 0.05
- 0.000.00%
LifeMD Newsroom
Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)
Lake Street Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
Mizuho Securities Maintains LifeMD(LFMD.US) With Hold Rating
Mizuho Securities Sticks to Its Hold Rating for LifeMD (LFMD)
Lake Street Initiates Coverage On LifeMD With Buy Rating, Announces Price Target of $12
Lake Street Starts Virtual Primary Care Provider LifeMD With a Buy
Lake Street Initiates LifeMD(LFMD.US) With Buy Rating, Announces Target Price $12
This Insider Has Just Sold Shares In LifeMD
Medifast Survey Finds Majority of U.S. Adults Trying to Lose Weight Agree Lifestyle Changes Are Essential – Even With Weight Loss Medications
LifeMD to Participate in the Mizuho Health Care Conference: Medical Device, Services, Technology and Distribution
What Is LifeMD, Inc.'s (NASDAQ:LFMD) Share Price Doing?
Mizuho Initiates Coverage On LifeMD With Neutral Rating, Announces Price Target of $7
LifeMD, Inc.'s (NASDAQ:LFMD) Market Cap Dropped US$62m Last Week; Individual Investors Who Hold 43% Were Hit as Were Institutions
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating
LifeMD to Participate in Three Investor Conferences During November
H.C. Wainwright Maintains LifeMD(LFMD.US) With Buy Rating, Maintains Target Price $12
LifeMD Analyst Ratings
Strong Revenue Growth and Strategic Initiatives Position LifeMD for Continued Expansion Despite Challenges
LifeMD, Inc. (LFMD) Q3 2024 Earnings Call Transcript Summary
Craig-Hallum Maintains LifeMD(LFMD.US) With Buy Rating, Announces Target Price $16